Artificial intelligence electrocardiogram as a novel screening tool to detect a newly abnormal left ventricular ejection fraction after anthracycline-based cancer therapy
An erratum to this article was published (Eur J Prev Cardiol, 27 Mar 2024 ↗)
Authors' conclusion
These data support the use of AI-ECG for cardiotoxicity screening after anthracycline-based chemotherapy.
Study context
- Population
- Female breast cancer patients with ECG and TTE before and after (neo)adjuvant anthracycline chemotherapy, without HER2-directed therapy, metastatic disease, second primary malignancy or pre-existing CVD20 cases and 683 controls analysed
- Participants
- 989 patients
- Comparison
- AI-ECG for detection of abnormal ejection fraction (EF) vs TTE
- Outcome
- Diagnostic performance of AI-ECG by AUC for EF < 50%
Methodological detailssingle-centre, consecutive cohort, 22 developed anthracycline-attributed EF decline over follow-up of 9.8 ± 4.2 years
- Single-centre
- Consecutive cohort
- 22 developed anthracycline-attributed EF decline over follow-up of 9.8 ± 4.2 years
Performance
As reported in the abstract
Detection of EF < 50% after anthracycline therapy
| Test or model | AUC |
|---|---|
| AI-ECG | 0.93 |
AI-ECG
AUC0.93
Further findings
| Outcome | Values |
|---|---|
| Detection of EF ≤ 35% after anthracycline therapy | AI-ECG AUC 0.94 |
Original publication
Artificial intelligence electrocardiogram as a novel screening tool to detect a newly abnormal left ventricular ejection fraction after anthracycline-based cancer therapy. Eur J Prev Cardiol. Published 7 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →